Published in FEBS Lett on March 25, 1996
Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Front Cell Infect Microbiol (2012) 1.18
Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr (2008) 1.10
Peptidomic profile of milk of Holstein cows at peak lactation. J Agric Food Chem (2013) 0.90
Casein fermentate of Lactobacillus animalis DPC6134 contains a range of novel propeptide angiotensin-converting enzyme inhibitors. Appl Environ Microbiol (2007) 0.90
Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines. Front Microbiol (2016) 0.86
Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study. Eur J Clin Nutr (2014) 0.86
Effects of 'casoparan', a peptide isolated from casein hydrolysates with mastoparan-like properties. Mediators Inflamm (2004) 0.78
Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis. Br J Clin Pharmacol (2016) 0.78
Chickpea protein hydrolysate as a substitute for serum in cell culture. Cytotechnology (2008) 0.78
Milk Intolerance, Beta-Casein and Lactose. Nutrients (2015) 0.76
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
[The taxonomic problem of Clostridium sordellii and Clostridium bifermentans]. Med Dosw Mikrobiol (1966) 1.72
Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang (2009) 1.60
Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. J Virol (1999) 1.54
Dobrava hantavirus causes hemorrhagic fever with renal syndrome in central Europe and is carried by two different Apodemus mice species. J Med Virol (2001) 1.42
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut (2009) 1.40
Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay. Eur J Clin Microbiol Infect Dis (1995) 1.28
Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr (2000) 1.22
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol (1996) 1.21
Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology (1997) 1.20
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res (1998) 1.17
Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology (1992) 1.15
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol (2001) 1.14
Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Am J Trop Med Hyg (1999) 1.11
Human cytomegalovirus (HCMV) encephalitis in an immunocompetent young person and diagnostic reliability of HCMV DNA PCR using cerebrospinal fluid of nonimmunosuppressed patients. J Clin Microbiol (1998) 1.05
Clinical characterization of Dobrava hantavirus infections in Germany. Clin Nephrol (2001) 1.04
Genetic characterization of a new hantavirus detected in Microtus arvalis from Slovakia. Virus Genes (1995) 0.95
Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology (1996) 0.94
Heterogeneity of hepatitis B virus C-gene sequences: implications for amplification and sequencing. J Hepatol (1993) 0.94
Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine beta-lactoglobulin. FEBS Lett (1997) 0.94
Life-threatening Dobrava hantavirus infection with unusually extended pulmonary involvement. Clin Nephrol (2004) 0.93
Bioactive peptides derived from milk proteins. Structural, physiological and analytical aspects. Nahrung (1995) 0.93
Nucleosides and nucleotides: natural bioactive substances in milk and colostrum. Br J Nutr (2000) 0.91
Detection of human hantavirus infections in Lithuania. Infection (2005) 0.90
Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine (1998) 0.90
Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol (2000) 0.90
[Prevalence of hantavirus infections in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2004) 0.90
Coding strategy of the S and M genomic segments of a hantavirus representing a new subtype of the Puumala serotype. Arch Virol (1995) 0.88
Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs. Antimicrob Agents Chemother (1991) 0.88
Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. Viral Immunol (2002) 0.88
Rational use of diagnostic tools in hepatitis C. J Hepatol (1996) 0.87
Lactokinins: whey protein-derived ACE inhibitory peptides. Nahrung (1999) 0.86
New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol (1999) 0.86
HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Biol Chem (1999) 0.86
Transmission of GBV-C/HGV from drug-addicted mothers to their babies. J Hepatol (1997) 0.85
Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology (1998) 0.85
Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol (1999) 0.85
Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol (1999) 0.83
Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology (1998) 0.83
Automated bed to aid pulmonary drainage and prevent decubitus ulcers. Med Biol Eng (1975) 0.82
Primary hepatic or splenic diffuse large B-cell lymphoma and hepatitis C virus infection: a non-fortuitous association? Ann Hematol (2000) 0.82
Caseinophosphopeptides and their cell modulating potential. Biofactors (2004) 0.82
Chemical characterization and opioid activity of an exorphin isolated from in vivo digests of casein. FEBS Lett (1986) 0.82
Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol (1990) 0.82
Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology (2000) 0.81
First molecular evidence for Puumala hantavirus in Slovakia. Virus Genes (2001) 0.81
[Prevalence of antibodies to hepatitis A, hepatitis B and hepatitis C viruses in the German population]. Gesundheitswesen (1999) 0.80
Leg load warning system for the orthopaedically handicapped. Med Biol Eng (1974) 0.80
DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection. J Biotechnol (2001) 0.80
Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells. J Gen Virol (1999) 0.80
Sensory ataxia in myelopathy with chronic hepatitis C virus infection. Neurology (2002) 0.80
Synthetic peptides corresponding to alpha-lactalbumin and beta-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. Biol Chem Hoppe Seyler (1996) 0.79
Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope. Intervirology (1999) 0.79
Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments. J Gen Virol (1997) 0.78
Warning device for the prevention of ischaemic ulcers in quadriplegics. Med Biol Eng (1976) 0.77
Interaction of wild-type and naturally occurring deleted variants of hepatitis B virus core polypeptides leads to formation of mosaic particles. FEBS Lett (2000) 0.77
Post-translational phosphorylation affects the IgE binding capacity of caseins. FEBS Lett (2000) 0.76
[Treatment of chronic hepatitis B with interferon alpha-2b]. Gastroenterol J (1990) 0.76
Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut (1993) 0.76
Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol (2005) 0.76
A new variant of progressive encephalomyelitis with rigidity associated with cerebellar ataxia and dementia: correlation of MRI and histopathological changes. A case report. Neurol Res (1997) 0.76
[Immunogenic properties of type E botulinum toxoid]. Med Dosw Mikrobiol (1965) 0.75
[Treatment of chronic hepatitis B with interferon alpha-2b]. Dtsch Med Wochenschr (1990) 0.75
[The mechanism of anaerobic gastrointestinal infection in man]. Pol Tyg Lek (1974) 0.75
Nutraceutical and functional food ingredients for food and pharmaceutical applications. Br J Nutr (2001) 0.75
[Studies on the type E of Clostridium botulinum. V. Hemolytic activity of the type E of botulinum toxin]. Med Dosw Mikrobiol (1965) 0.75
[The association of hepatitis-B-virus infection and hepatocellular carcinoma]. Z Arztl Fortbild (Jena) (1991) 0.75
Comparison of direct and indirect two-site binding enzyme immunoassay. Clin Chim Acta (1982) 0.75
[Hepatitis and imported infectious diseases. A. Hepatitis. 1. Virologic findings in acute hepatitis]. Z Gesamte Inn Med (1983) 0.75
Natural history of hepatitis C. Mem Inst Oswaldo Cruz (2000) 0.75
[In Memoriam: Professor and Doctor in Medical Sciences Stanislaw Legezyński]. Postepy Hig Med Dosw (1971) 0.75
[Risk of hepatitis B in endoscopy personnel]. Dtsch Z Verdau Stoffwechselkr (1981) 0.75
[Clinical studies on evaluation of the TNM classification of the oral carcinoma]. Dtsch Zahnarztl Z (1973) 0.75
[Structure and stereochemistry of (-)-10-oxominovincin]. Pharmazie (1971) 0.75
Giving. West J Med (1991) 0.75
[The relation of B- and non-A, non-B hepatitis virus--hepatitis B virus (HBV) DNA hybridization studies of the sera in non-A, non-B hepatitis]. Z Gesamte Inn Med (1989) 0.75
Thermal response of paraplegic skin to the application of localized pressure. Arch Phys Med Rehabil (1981) 0.75
[Alkaloids from Vinca minor L]. Tetrahedron Lett (1968) 0.75
[Anaerobic bacteremia and septicemia]. Przegl Epidemiol (1975) 0.75
[Vinomin, an additional alkaloid of Vinca minor]. Pharmazie (1971) 0.75
Dysregulated Epstein-Barr virus infection in patients with CIDP. J Neuroimmunol (2009) 0.75
[16-methoxyvincadifformin, a new alkaloid from Vinca minor]. Pharmazie (1968) 0.75
[Maternal hepatitis B infection as the cause of nonimmunologic hydrops fetalis]. Z Geburtshilfe Neonatol (1999) 0.75
Structure and selection of hepatitis B virus variants during the natural course of infection and interferon therapy. Princess Takamatsu Symp (1995) 0.75
Comparison of three different recombinant hepatitis B virus core particles expressed in Escherichia coli. Arch Virol (1994) 0.75
Fluorographic determination of 3H-labeled hepatitis B virus DNA and other viral DNAs. Z Med Lab Diagn (1986) 0.75
In vitro generation and stability of the lactokinin beta-lactoglobulin fragment (142-148). J Dairy Sci (2004) 0.75
[Dimethoxyeburnamonine, a new alkaloid from Vinca minor]. Pharmazie (1968) 0.75
[Recommendations for the detection, prevention and control of viral hepatitis]. Z Arztl Fortbild (Jena) (1990) 0.75
[Studies on Clostridium botulinum type E. VI. Binding power of the type E of botulinum toxin]. Med Dosw Mikrobiol (1965) 0.75
[Effect of glucose and hyaluronic acid on hyaluronidase level in the supernatants of Clostridium perfringens type A]. Med Dosw Mikrobiol (1966) 0.75
[The structure of a new alkaloid of Vinca minor]. Tetrahedron Lett (1968) 0.75
Acrylamide-occurrence in mixed concentrate feed for dairy cows and carry-over into milk. Food Addit Contam (2005) 0.75
Semi-preparative isolation of phosphopeptides derived from bovine casein and dephosphorylation of casein phosphopeptides. Nahrung (1996) 0.75
[Various serologic problems concerning the classification and analysis of the structure of Clostridia]. Bull Off Int Epizoot (1969) 0.75
[Immunoenzyme assay for the demonstration of antibodies against hepatitis B surface antigen (anti-HBs)]. Z Med Lab Diagn (1986) 0.75
[Problem of taxonomy of Clostridium sordellii and Clostridium bifermentans]. Med Dosw Mikrobiol (1967) 0.75
[Hepatitis B screening in pregnant patients and their children. A Greifswald perinatology-pediatric study. II. Pediatric findings]. Zentralbl Gynakol (1989) 0.75
Short communication: bovine kappa-casein variants result in different angiotensin I converting enzyme (ACE) inhibitory peptides. J Dairy Sci (2009) 0.75